Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: robotics/AI – Page 1,738

This article is part of our reviews of AI research papers, a series of posts that explore the latest findings in artificial intelligence.

Creating machines that have the general problem–solving capabilities of human brains has been the holy grain of artificial intelligence scientists for decades. And despite tremendous advances in various fields of computer science, artificial general intelligence still eludes researchers.

Our current AI methods either require a huge amount of data, or a very large number of hand-coded rules, and they’re only suitable for very narrow domains. AGI, on the other hand, should be able to perform multiple tasks with little data and specific instructions.

Read more | >

Scanning lasers—from barcode scanners at the supermarket to cameras on newer smartphones—are an indispensable part of our daily lives, relying on lasers and detectors for pinpoint precision.

Distance and using LiDAR—a portmanteau of light and radar—is becoming increasingly common: reflected beams record the surrounding environment, providing crucial data for autonomous cars, agricultural machines, and factory robots.

Current technology bounces the laser beams off of moving mirrors, a mechanical method that results in slower scanning speeds and inaccuracies, not to mention the large physical size and complexity of devices housing a laser and mirrors.

Read more | >

The use of artificial intelligence (A.I.) and machine learning (ML), technologies that help people and organizations handle customer personalization and communication, data analytics and processing, and a host of other applications continues to grow.

An IDC report found three-quarters of commercial enterprise applications could lean on A.I. by next year alone, while an Analytics Insight report projects more than 20 million available jobs in artificial intelligence by 2023.

Due to A.I. and ML’s transformational reach, specialists with the right skills could find themselves with job opportunities across a wide range of industries. A global skills gap in the technologies means qualified applicants can expect good salaries and a strong bargaining position.

Read more | >


AgelessRx claims that PEARL is the first nationwide telemedicine trial and one of the first large-scale intervention trials on Longevity. The human trial is a stepping stone to the way to bringing rapamycin to the Longevity market. PEARL (Participatory Evaluation of Aging with Rapamycin for Longevity) is a $600,000 trial with the University of California. They will evaluate the safety and effectiveness of rapamycin in 200 healthy adults for Longevity in double-blind, randomized, placebo-controlled trial.

Interested patients will be screened for eligibility using telemedicine. Eligible patients include those aged 50–85 of any sex, any ethnicity, in relatively good health, with only well-managed, clinically stable chronic diseases.

TAME is a separate $75 million trial to clinically evaluate Metformin drugs for Longevity properties. TAME has a composite primary endpoint – of stroke, heart failure, dementia, myocardial infarction, cancer and death. Rather than attempting to cure one endpoint, it will look to delay the onset of any endpoint, extending the years in which subjects remain in good health – their healthspan. A $40 million donation has been combined with a $35 million NIH grant to fund the TAME trial.

Read more | >